{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:47:46Z","timestamp":1772239666826,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.clgc.2016.10.006","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T17:18:25Z","timestamp":1477588705000},"page":"463-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Rana R.","family":"McKay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn J.","family":"Bubley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.10.006_bib1","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.006_bib2","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.006_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.006_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601127","article-title":"Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer","volume":"89","author":"Edwards","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.10.006_bib5","first-page":"1383","article-title":"Functional characterization of mutant androgen receptors from androgen-independent prostate cancer","volume":"3","author":"Fenton","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.006_bib6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A\u00a0clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2016.10.006_bib7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2016.10.006_bib8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.006_bib9","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","article-title":"Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase\/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer","volume":"7","author":"Vasaitis","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2016.10.006_bib10","doi-asserted-by":"crossref","first-page":"27440","DOI":"10.18632\/oncotarget.4578","article-title":"Galeterone and VNPT55 induce proteasomal degradation of AR\/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in\u00a0vivo","volume":"6","author":"Kwegyir-Afful","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2016.10.006_bib11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1078-0432.CCR-15-1432","article-title":"Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer","volume":"22","author":"Montgomery","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.006_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.10.006_bib13","doi-asserted-by":"crossref","first-page":"7654","DOI":"10.1038\/srep07654","article-title":"Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer","volume":"5","author":"Qu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2016.10.006_bib14","first-page":"21","article-title":"Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer","volume":"8","author":"Takeuchi","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.clgc.2016.10.006_bib15","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2016.10.006_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.clgc.2016.10.006_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.006_bib18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.006_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.006_bib20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.006_bib21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.006_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.10.006_bib23","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.006_bib24","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.006_bib25","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.006_bib26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cncr.28518","article-title":"Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment","volume":"120","author":"Badrising","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.10.006_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/pcan.2014.53","article-title":"Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and\/or docetaxel","volume":"18","author":"Cheng","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2016.10.006_bib28","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/pros.22874","article-title":"Clinical activity of enzalutamide in docetaxel-naive and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer","volume":"74","author":"Nadal","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2016.10.006_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eururo.2013.06.042","article-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","volume":"65","author":"Schrader","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.10.006_bib30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","article-title":"The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer","volume":"66","author":"Schweizer","year":"2014","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:28:24Z","timestamp":1761564504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316303159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1558767316303159"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.10.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}